EvolverAI® 2.0– Accelerating
Innovation, Transforming Lives
At BioXcel, we believe there is nothing more important than helping people live healthier, longer lives. Our proprietary AI platform, EvolverAI® 2.0, is the engine behind that mission—harnessing the power of artificial intelligence and human expertise to transform how new medicines are discovered, developed, and delivered.
Turning Potential Into Proof: From Molecule to Medicine
Our platform’s potential was realized with the discovery and development of IGALMI™ (dexmedetomidine)— a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Using EvolverAI and BioXcel, Therapeutics identified and advanced this first-in-class asset from concept to FDA approval in just four years.
This success showcases the unique strength of pairing scientific acumen with AI-driven discovery— addressing unmet clinical needs with unprecedented speed.
EvolverAI Platform Data Foundation
EvolverAI is built on an extensive and diverse dataset, including:
Inside the Engine: What Powers EvolverAI® 2.0
EvolverAI® 2.0 is built at the intersection of advanced machine learning and biomedical expertise. What makes this platform powerful is not just its algorithms—but the rich, multi-modal data and real-world knowledge that fuels them.
Key Features
- Metadata Generation: Uses NLP and relationship mapping to extract deep contextual insights from scientific literature, clinical data, and more
- Knowledge Graph Creation: Synthesizes structured and unstructured data to build dynamic, interpretable knowledge graphs
- 100+ Proprietary AI Models: These models reason across diverse datasets—clinical, genomic, phenotypic, and pharmacological—to uncover hidden therapeutic connections
- Expert-Guided Intelligence: All models are trained and validated by a multidisciplinary team of scientists and clinicians with vast drug discovery experience
AI-Driven Insights
EvolverAI 2.0 supports a wide range of strategic and operational decision-making areas, including:
Opportunity Assessment
Identify top diseases, compounds, and companies for strategic focus
Licensing & Due Diligence
Accelerate partner evaluation and risk mitigation
Organizational Benchmarking
Evaluate and compare external R&D portfolios
Pipeline & Therapy Area Assessments
Guide resource allocation with data-driven clarity
Investment Thesis & Recommendations
Guide portfolio and pipeline decisions with confidence
Therapeutic Franchise Strategy
Develop focused, scalable therapeutic verticals
Indication/Target/Asset Prioritization
Streamline selection of high-potential programs
Drug Re-Innovation
Repurpose or reposition underutilized assets
Commercial Attractiveness
Analyze ROI potential and market dynamics
More Efficient Drug Development
EvolverAI® 2.0 reduces the time, cost, and risk associated with traditional drug development by:
- Shortening discovery timelines
- Lowering attrition by prioritizing high-probability candidates
- Reducing R&D costs via targeted, data-informed decision-making
- Building robust, de-risked pipelines with therapeutic precision
Whether discovering new molecular entities or reimagining existing compounds, EvolverAI is unlocking therapeutic possibilities at scale.
Built for Breakthroughs
EvolverAI® 2.0 is more than a platform—it’s a launchpad for innovation. By integrating AI with scientific expertise, we are charting a faster, smarter course for life-saving drug discovery.
We are only steps away from the next wave of transformative therapies—and EvolverAI is leading the way.
Let’s Collaborate
We partner with BioPharma companies worldwide to unlock the full potential of their R&D pipelines—enhancing discovery, accelerating timelines, and reducing risk.
Schedule a call with us to learn how EvolverAI® 2.0 can help your team uncover new opportunities, reimagine existing assets, and transform your development strategy.
Contact US
info@bioxcel.com
+1 475 237 9007